Palisade bio announces closing of $13.8 million upsized underwritten public offering and full exercise of over-allotment option

Carlsbad, calif., aug. 16, 2022 (globe newswire) -- palisade bio (nasdaq: pali), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (gi) complications, today announced the closing of its previously announced underwritten public offering for gross proceeds of approximately $13.8 million, prior to deducting underwriting discounts and commissions and offering expenses, including full exercise of the underwriter's over-allotment option to purchase additional common stock shares and warrants.
PALI Ratings Summary
PALI Quant Ranking